NHS risks losing revenue without data strategy

Think tank Reform has warned that the National Health Service risks losing out on huge potential revenue in the future if it does not put in place a strategy to capitalise on the increasing value of its medical data.

Read on PharmaTimes

Roche’s Daniel O’Day to become Gilead's chief executive

Gilead Sciences has announced that Daniel O'Day, the current CEO of Roche's pharmaceutical unit, will become their chief executive effective from March 1 next year. Daniel will replace current CEO John Milligan, after Gilead revealed that John will step down at the end of 2018.

Read on PharmaTimes

AI app decreases symptoms of COPD, study finds

A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD).

Read on PharmaTimes

SMC accepts four medicines for NHS use

Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.

Read on PharmaTimes

Health secretary orders review overprescribing

Health secretary Matt Hancock has ordered a review of patients who take multiple medicines, to ensure they are receiving the most appropriate treatment for their needs, and avoid needless overprescribing.

Read on PharmaTimes

1 2 3

Top of page

Industry News

Think tank Reform has warned that the National Health Service risks losing out on huge potential revenue in the future...
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us